A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Dinutuximab; Isotretinoin
- Indications Neuroblastoma
- Focus Adverse reactions
- 14 Feb 2019 Status changed from suspended to active, no longer recruiting.
- 05 Jun 2018 Results determining tolerability presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 13 Feb 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.